The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Due to the refractory and partial sensitive treatments to malignant cancers, immunotherapy
has increasingly become a hotspot in effective anti-tumor research. However, at present …

Immunotherapy is at the forefront of cancer treatment. The advent of numerous novel
approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive …

The field of immuno-oncology is now at the forefront of cancer care and is rapidly evolving.
The immune checkpoint blockade has been demonstrated to restore antitumor responses in …

Establishing appropriate preclinical models is essential for cancer research. Evidence
suggests that cancer is a highly heterogeneous disease. This follows the growing use of …

Simple Summary Patient-derived xenografts (PDX) are valuable models in preclinical
oncology drug development. However, they are not well suited for testing immune-based …

Simple Summary A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …

Metastatic melanoma is a complex and deadly disease. Due to its complexity, the
development of novel therapeutic strategies to inhibit metastatic melanoma remains an …

Despite targeted therapies and immunotherapies have revolutionized the treatment of
cancer patients, only a limited number of patients have long-term responses. Moreover, due …

Angiogenesis supplies oxygen and nutrients to growing tumors. Inhibiting angiogenesis may
stop tumor growth, but vascular endothelial growth factor inhibitors have limited effect in …